AbbVie also spoke about the disappointing data from Phase II studies of emraclidine in schizophrenia – a drug acquired as ...

The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company with a market capitalization of $311.86 billion, has been at the forefront of the industry with its diverse portfolio of pharmaceuticals ...

AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth ...

Both organisations will expand research and development efforts, improve digital frameworks for clinical trials, and adopt innovative trial models. The agreement was signed by NTUH President Ming ...

Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion ...

Medable Inc., a leading provider of clinical development technology, today announced new data from the Tufts Center for the Study of Drug Development (CSDD)’s PACT Consortium links decentralized ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and ...

Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tim Anderson from Bank of ...